Shares of biopharmaceutical company PDS Biotechnology (NASDAQ:PDSB) are on the rise today after it announced interim data from a Phase 2 study evaluating the combination of PDS0101 and Merck’s (NYSE:MRK) Keutruda for the treatment of HPV-16 positive head and neck squamous cell carcinoma (HNSCC) patients.
In the study, the drug combination was observed to be well tolerated and had an overall survival rate of 87.1% at 12 months. Further, median progression-free survival was 10.4 months alongside a disease control rate of 70.6%.
Importantly, the findings support a global confirmatory study and the company is now planning to initiate the trial this year.
After rising nearly 35% over the past year, PDSB shares are up a further 28% at the time of writing today.
Read full Disclosure
